Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 14 | 2024 | 798 | 3.520 |
Why?
|
| Mohs Surgery | 10 | 2024 | 42 | 3.120 |
Why?
|
| SEER Program | 2 | 2024 | 194 | 1.680 |
Why?
|
| Dermatologic Surgical Procedures | 3 | 2024 | 45 | 1.490 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 31 | 1.230 |
Why?
|
| Nose | 3 | 2023 | 92 | 1.180 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2019 | 15 | 1.090 |
Why?
|
| Rhinoplasty | 2 | 2023 | 44 | 0.970 |
Why?
|
| Paget Disease, Extramammary | 1 | 2024 | 4 | 0.930 |
Why?
|
| Nail Diseases | 2 | 2015 | 14 | 0.920 |
Why?
|
| Surgical Flaps | 3 | 2024 | 206 | 0.900 |
Why?
|
| Dermatofibrosarcoma | 1 | 2024 | 17 | 0.890 |
Why?
|
| Skin Transplantation | 2 | 2013 | 60 | 0.850 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 152 | 0.800 |
Why?
|
| Counseling | 1 | 2023 | 218 | 0.770 |
Why?
|
| Skin | 2 | 2018 | 505 | 0.770 |
Why?
|
| Lidocaine | 2 | 2024 | 48 | 0.740 |
Why?
|
| Anesthetics, Local | 2 | 2024 | 80 | 0.710 |
Why?
|
| Cicatrix | 2 | 2012 | 124 | 0.680 |
Why?
|
| Acrospiroma | 1 | 2019 | 5 | 0.650 |
Why?
|
| Facial Neoplasms | 1 | 2019 | 19 | 0.640 |
Why?
|
| Bandages | 2 | 2024 | 55 | 0.630 |
Why?
|
| Fissure in Ano | 1 | 2018 | 6 | 0.610 |
Why?
|
| Vulvar Diseases | 1 | 2018 | 11 | 0.610 |
Why?
|
| Infliximab | 1 | 2018 | 66 | 0.600 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 651 | 0.600 |
Why?
|
| Alternariosis | 1 | 2016 | 1 | 0.550 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 2 | 0.550 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 116 | 0.550 |
Why?
|
| Immunocompetence | 1 | 2016 | 33 | 0.540 |
Why?
|
| Drug Storage | 1 | 2016 | 17 | 0.520 |
Why?
|
| Methotrexate | 1 | 2018 | 343 | 0.520 |
Why?
|
| Syringes | 1 | 2016 | 24 | 0.520 |
Why?
|
| Drug Contamination | 1 | 2016 | 36 | 0.520 |
Why?
|
| Security Measures | 1 | 2015 | 4 | 0.510 |
Why?
|
| Skin Diseases, Genetic | 1 | 2015 | 6 | 0.510 |
Why?
|
| Contracture | 1 | 2015 | 24 | 0.500 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 265 | 0.490 |
Why?
|
| Dermatology | 1 | 2015 | 34 | 0.490 |
Why?
|
| Epinephrine | 1 | 2016 | 175 | 0.480 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 120 | 0.480 |
Why?
|
| Crohn Disease | 1 | 2018 | 281 | 0.480 |
Why?
|
| Photography | 1 | 2015 | 92 | 0.480 |
Why?
|
| Skin Diseases | 1 | 2015 | 124 | 0.460 |
Why?
|
| Models, Anatomic | 1 | 2015 | 98 | 0.450 |
Why?
|
| Cyanoacrylates | 1 | 2013 | 12 | 0.450 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 85 | 0.450 |
Why?
|
| Tissue Adhesives | 1 | 2013 | 35 | 0.440 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 38 | 0.440 |
Why?
|
| Eyelid Neoplasms | 1 | 2014 | 43 | 0.440 |
Why?
|
| Nails | 1 | 2013 | 17 | 0.440 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2013 | 71 | 0.440 |
Why?
|
| Ear Neoplasms | 1 | 2013 | 12 | 0.420 |
Why?
|
| Aged | 12 | 2024 | 19108 | 0.410 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 4 | 0.410 |
Why?
|
| Ointments | 1 | 2012 | 13 | 0.410 |
Why?
|
| Zinc Oxide | 1 | 2012 | 7 | 0.410 |
Why?
|
| Humans | 31 | 2024 | 123180 | 0.400 |
Why?
|
| Bowen's Disease | 1 | 2011 | 4 | 0.380 |
Why?
|
| Clinical Competence | 1 | 2018 | 973 | 0.370 |
Why?
|
| Melanoma | 3 | 2024 | 824 | 0.360 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 68 | 0.360 |
Why?
|
| Ochronosis | 1 | 2010 | 2 | 0.360 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3670 | 0.360 |
Why?
|
| Postoperative Care | 1 | 2013 | 295 | 0.360 |
Why?
|
| Explosive Agents | 1 | 2010 | 4 | 0.360 |
Why?
|
| Metals | 1 | 2010 | 62 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 481 | 0.320 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6375 | 0.290 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 87 | 0.290 |
Why?
|
| Choroid Neoplasms | 1 | 2007 | 25 | 0.280 |
Why?
|
| Retrospective Studies | 7 | 2024 | 16062 | 0.270 |
Why?
|
| Male | 14 | 2024 | 60173 | 0.270 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 198 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2396 | 0.260 |
Why?
|
| Wound Healing | 2 | 2023 | 451 | 0.240 |
Why?
|
| Biopsy | 2 | 2019 | 1236 | 0.240 |
Why?
|
| Female | 13 | 2024 | 65562 | 0.230 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2024 | 46 | 0.220 |
Why?
|
| Population Health | 1 | 2024 | 37 | 0.210 |
Why?
|
| Nasolabial Fold | 1 | 2022 | 1 | 0.210 |
Why?
|
| Middle Aged | 7 | 2024 | 26015 | 0.210 |
Why?
|
| Suture Techniques | 1 | 2023 | 196 | 0.190 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 476 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12142 | 0.180 |
Why?
|
| Chin | 1 | 2019 | 4 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1876 | 0.160 |
Why?
|
| United States | 2 | 2024 | 10660 | 0.160 |
Why?
|
| Roman World | 1 | 2018 | 2 | 0.150 |
Why?
|
| Greece, Ancient | 1 | 2018 | 10 | 0.150 |
Why?
|
| History, Medieval | 1 | 2018 | 27 | 0.150 |
Why?
|
| History, Ancient | 1 | 2018 | 54 | 0.150 |
Why?
|
| Adult | 5 | 2024 | 29032 | 0.150 |
Why?
|
| History, 19th Century | 1 | 2018 | 115 | 0.150 |
Why?
|
| Granuloma | 1 | 2018 | 68 | 0.150 |
Why?
|
| India | 1 | 2018 | 217 | 0.150 |
Why?
|
| Adolescent | 3 | 2024 | 19111 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 350 | 0.140 |
Why?
|
| Physical Examination | 1 | 2018 | 163 | 0.140 |
Why?
|
| Econazole | 1 | 2016 | 2 | 0.140 |
Why?
|
| Itraconazole | 1 | 2016 | 24 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 234 | 0.140 |
Why?
|
| Incidence | 1 | 2024 | 3045 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 381 | 0.130 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 115 | 0.130 |
Why?
|
| Buffers | 1 | 2016 | 31 | 0.130 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 89 | 0.130 |
Why?
|
| Bicarbonates | 1 | 2016 | 98 | 0.130 |
Why?
|
| Skin Aging | 1 | 2015 | 14 | 0.130 |
Why?
|
| Hip Joint | 1 | 2015 | 38 | 0.120 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 73 | 0.120 |
Why?
|
| Vitamin A | 1 | 2015 | 59 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 137 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2016 | 269 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 198 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2024 | 3327 | 0.120 |
Why?
|
| Eccrine Glands | 1 | 2014 | 1 | 0.120 |
Why?
|
| Steroids | 1 | 2015 | 201 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 25 | 0.110 |
Why?
|
| Hair Follicle | 1 | 2014 | 34 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2016 | 286 | 0.110 |
Why?
|
| Risk Factors | 2 | 2024 | 10031 | 0.110 |
Why?
|
| Pressure | 1 | 2013 | 129 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2012 | 50 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 239 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2015 | 861 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 604 | 0.100 |
Why?
|
| Fibrosis | 1 | 2014 | 429 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2012 | 141 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2840 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 331 | 0.090 |
Why?
|
| Cytoplasmic Granules | 1 | 2010 | 47 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1688 | 0.080 |
Why?
|
| Young Adult | 1 | 2024 | 8864 | 0.080 |
Why?
|
| Child | 2 | 2024 | 24247 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3375 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 1176 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 1403 | 0.070 |
Why?
|
| Orbital Neoplasms | 1 | 2007 | 65 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6221 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1139 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 2024 | 48 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2024 | 358 | 0.050 |
Why?
|
| Sutures | 1 | 2023 | 67 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2024 | 256 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1585 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 1311 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3235 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 18 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 17 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3547 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 100 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 423 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6029 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2015 | 399 | 0.030 |
Why?
|
| Comorbidity | 1 | 2012 | 1497 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 17542 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 33798 | 0.010 |
Why?
|